Inflammatory bowel disease (IBD) is a chronic, relapsing, inflammatory disorder of the gastrointestinal tract and includes Ulcerative Colitis (UC) and Crohn’s Disease (CD). IBD affects over 5 million people worldwide, and the incidence has been growing steadily over the past 10 years.
While the exact cause of IBD is unknown, the inflammation results from the immune system’s response to environmental triggers. Today, the goal of treatment is to bring about and maintain remission, and a range of advanced treatment options are available to reduce inflammation and manage symptoms. The area is one of the most active in biopharmaceutical development and clinical research with hundreds of active trials in progress.
In the past seven years, we’ve conducted:
ICON offers end-to-end services to support the development of your product to treat Inflammatory Bowel Disease. In the past seven years, we’ve conducted over 15 studies in Crohn’s disease and over 35 in Ulcerative Colitis, giving us a profound understanding of the clinical and operational challenges in this therapeutic area. Such immersion translates into strong development plans, efficient study management, defensible data packages, and careful preparation for commercial success.